| abstract |
The present invention relates to a quinolein derivative of the formula (I) (see Formula) or any of its pharmaceutically acceptable salts, or any of its metabolites, for use in treating or preventing a viral infection, in particular an infection caused for HIV or an HIV-related condition in a patient; and then finish the treatment when: the viral load is low or undetectable; and / or the CD4 + cell count level is maintained or restored. The present invention further relates to a quinolein derivative of the formula (I) as defined in claim 1, or any of its pharmaceutically acceptable salts and metabolites, for use in treating or preventing a viral infection, in particular an infection. caused by HIV or an HIV-related condition in a patient, for which an inefficiency or a decrease in the efficacy of a prior antiretroviral treatment and a quinolein derivative of the formula (I) as defined above has been indicated, or any of its pharmaceutically acceptable salts and metabolites, for use to treat or prevent a viral infection, in particular an infection caused by HIV or an HIV-related condition in a patient, wherein the patient is infected by a viral strain resistant to drugs, and more particularly for a drug resistant HIV strain. |